Table 3.
Comparison of Clinical Backgrounds of 5-Aminolevulinic Acid-pretreated Patients Who Underwent Neurosurgery and Urological Surgery.
| NeuroSRG | Urological-SRG | P-value | |
|---|---|---|---|
| Number | 17 | 26 | |
| Age | 64 [47–72] | 73 [63–77] | 0.098 |
| Sex | 0.002 | ||
| Female | 11 (64.7%) | 4 (15.4%) | |
| Male | 6 (35.3%) | 22 (84.6%) | |
| BMI (kg/m2) | 22.4 [20.6–24.6] | 23.0 [20.8–24.3] | 0.759 |
| KPS score | 60 [50–60] | 100 [100–100] | <0.001 |
| Tumor | |||
| Recurrence | 7 (41.2%) | 13 (50.0%) | 0.756 |
| Tumor size | N/A | ||
| MRI volume (cm3) | 37.6 [34.5–81.1] | N/A | |
| T (TNM classification) | N/A | ||
| Ta | 11 (42.3%) | ||
| T1 | 7 (26.9%) | ||
| T2 | 0 (0.0%) | ||
| CIS | 5 (19.2%) | ||
| Others | 3 (11.5%) | ||
| Comorbidity | 7 (41.2%) | 20 (76.9%) | 0.026 |
| Hypertension | 5 (29.4%) | 13 (50.0%) | 0.219 |
| Diabetes mellitus | 0 (0.0%) | 9 (34.6%) | 0.007 |
| Heart disease | 0 (0.0%) | 6 (23.1%) | 0.066 |
| Hyperlipidemia | 3 (17.6%) | 6 (23.1%) | 1.000 |
| CKD | 0 (0.0%) | 7 (26.9%) | 0.031 |
| Stroke | 0 (0.0%) | 1 (3.8%) | 1.000 |
| Antihypertensives | 5 (29.4%) | 13 (50.0%) | 0.219 |
| RAS inhibitor | 3 (17.6%) | 9 (34.6%) | 0.306 |
| β-Blocker | 0 (0.0%) | 1 (3.8%) | 1.000 |
| Ca antagonist | 2 (11.8%) | 7 (26.9%) | 0.281 |
| Laboratory data | |||
| Alb (g/dL) | 3.8 [3.5–4.2] | 4.2 [3.9–4.2] | 0.021 |
| Hb (g/dL) | 12.6 [11.3–14.1] | 14.4 [13.9–15.2] | 0.001 |
| SBP <80mmHg (T4) | 7 (41.2%) | 10 (40.0%) | 1.000 |
Note: Data are presented as median [interquartile range] and numbers (proportion).
Abbreviations: NeuroSRG, patients who underwent neurosurgery; urological-SRG, patients who underwent urological surgery; KPS, Karnofsky Performance Status; CKD, chronic kidney disease (estimated glomerular filtration rate <60mL/min/1.73m2); RAS, renin-angiotensin system; SBP, systolic blood pressure; T4, around 4 h after the pretreatment (intraoperatively); N/A, not available.